Bulletin
Investor Alert

Alexion Pharmaceuticals Inc.

NAS: ALXN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 3, 2021, 7:40 p.m.

/zigman2/quotes/206262068/composite

$

144.00

Change

-4.19 -2.83%

Volume

Volume 129,592

Quotes are delayed by 20 min

/zigman2/quotes/206262068/composite

Today's close

$ 150.37

$ 148.19

Change

-2.18 -1.45%

Day low

Day high

$148.14

$150.63

Open

52 week low

52 week high

$72.67

$162.60

Open

John J. Orloff

Currently, John J. Orloff occupies the position of Executive VP, Head-Research & Development at Alexion Pharmaceuticals, Inc.

In the past Dr. Orloff occupied the position of Director at Novelion Therapeutics, Inc., Chief Scientific Officer, EVP, Global Head-R&D at Baxalta, Inc., Vice President, Global Head-Research & Development at Baxter BioScience Corp., Chief Medical Officer & Senior Vice President for Novartis Pharma AG and Executive Vice President & Head-Research at Aegerion Pharmaceuticals, Inc.

John J. Orloff received an undergraduate degree from Dartmouth College and a doctorate from the University of Vermont College of Medicine.

Transactions

Date Shares Transaction Value
12/16/2020 3,261   Derivative/Non-derivative trans. at $157.96 per share. 515,108
12/16/2020 18,134   Derivative/Non-derivative trans. at $157.96 per share. 2,864,447
12/16/2020 40,677   Award at $0 per share. 0
12/15/2020 40   Award at $93.53 per share. 3,741
06/08/2020 2,784   Derivative/Non-derivative trans. at $114.61 per share. 319,075
03/02/2020 1,396   Derivative/Non-derivative trans. at $90.54 per share. 126,394
02/28/2020 10,880   Award at $0 per share. 0
12/15/2019 38   Award at $93.86 per share. 3,566
06/07/2019 2,786   Derivative/Non-derivative trans. at $118.61 per share. 330,448
02/28/2019 9,428   Award at $0 per share. 0
02/28/2019 675   Derivative/Non-derivative trans. at $132.92 per share. 89,721
12/15/2018 34   Award at $93.01 per share. 3,162
06/08/2018 2,115   Disposition at $118.53 per share. 250,691
02/28/2018 8,940   Award at $0 per share. 0
06/07/2017 24,965   Award at $0 per share. 0

Officers and Executives

Dr. Ludwig N. Hantson
Chief Executive Officer & Director
Dr. Aradhana Sarin
Chief Financial Officer & Executive Vice President
Mr. Brian M. Goff
Chief Commercial, Global Operations Officer & EVP
Mr. George Llado
Chief Information Officer & Senior Vice President
Dr. John J. Orloff
Executive VP, Head-Research & Development
Dr. Tanisha V. Cariño
Chief Corporate Affairs Officer & EVP
Dr. Gianluca Pirozzi
Head-Clinical Development, Hematology & Nephrology
Mr. Uzair Qadeer
Chief Diversity Officer
Ms. Becky Lillie
Chief Human Experience Officer
Ms. Tamar Thompson
Vice President-US Government Affairs & Policy
Ms. Indrani M. Franchini
Chief Compliance Officer & Executive VP
Ms. Rana Strellis
SVP-Global Culture & Social Responsibility
Mr. Daniel A. Bazarko
Chief Accounting Officer & Senior Vice President
Mr. Christopher J. Stevo
Head-Investor Relations1
Ms. Morgan Sanford
Chief of Staff
Ms. Ellen V. Chiniara
Secretary, Chief Legal Officer & Executive VP
Mr. David Richard Brennan
Chairman
Dr. Andreas Rummelt
Independent Director
Mr. John T. Mollen
Independent Director
Mr. Christopher J. Coughlin
Independent Director
Dr. Paul A. Friedman
Independent Director
Dr. Francois Nader
Independent Director
Dr. Deborah L. Dunsire
Independent Director
Ms. Judith A. Reinsdorf
Independent Director
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.